CS
GILD icon

Capital Square’s Gilead Sciences GILD Stock Holding History

Capital Square’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,363
Closed -$242K – 160
2021
Q4 		$242K Sell
3,363
-1
-0% -$69 0.17% 131
2021
Q3 		$230K Hold
3,364
– – 0.16% 138
2021
Q2 		$230K Sell
3,364
-114
-3% -$7.61K 0.17% 131
2021
Q1 		$226K Hold
3,478
– – 0.17% 132
2020
Q4 		$202K Hold
3,478
– – 0.17% 138
2020
Q3 		$219K Sell
3,478
-204
-6% -$14.1K 0.23% 117
2020
Q2 		$283K Sell
3,682
-198
-5% -$15.2K 0.3% 100
2020
Q1 		$290K Buy
3,880
+87
+2% +$6.01K 0.34% 87
2019
Q4 		$246K Buy
+3,793
New +$247K 0.23% 106

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital Square's GILD Position: Q1 2022 in Review

Capital Square sold out of Gilead Sciences (GILD) in Q1 2022, closing a stake of 3,363 shares — an estimated $242K sold.

Capital Square first reported a position in GILD in Q4 2019 and held it in 9 quarters. The position peaked at $290K in Q1 2020. 1,600 funds tracked by Wall St. Rank hold GILD as of Q1 2022.

  • Capital Square reported no remaining Gilead Sciences position as of Q1 2022 after selling out during the quarter.
  • Capital Square sold 3,363 Gilead Sciences shares in Q1 2022, an estimated $242K.
  • Capital Square first reported a position in Gilead Sciences in Q4 2019 and held it in 9 quarters.
  • Capital Square's Gilead Sciences position peaked at $290K in Q1 2020.
  • 1,600 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.

Based on Capital Square's 13F filing for Q1 2022, filed 9 May 2022.